Ventracor (ASX:VCR) Announces European Approval For New Version VentrAssist LVAD
Main Category: Cardiovascular / CardiologyAlso Included In: Regulatory Affairs / Drug Approvals; Medical Devices / Diagnostics
Article Date: 19 Dec 2007 - 2:00 PDT
| Patient / Public: | ![]() |
1 (1 votes) |
| Healthcare Prof: | ![]() |
Ventracor (ASX: VCR) announced CE Marking approval for the next version of the VentrAssist(tm) left ventricular assist device (LVAD) which allows it to be marketed and sold in Europe.
The US Food & Drug Administration (FDA) approved use of the new version earlier this week.
The new version VentrAssist (called LVA4) was first implanted in Australia under the Special Access Scheme (SAS) and an application for full approval is with the Australian Therapeutic Goods Administration for review.
Ventracor Chief Executive Peter Crosby said, "The enhanced VentrAssist will help us continue to meet the needs of our partner cardiologists and surgeons and help them achieve better clinical outcomes for their heart failure patients.
The new version uses the proven VentrAssist blood pump with a thinner percutaneous lead (the wire from the pump that goes through the skin) which it is hoped will lower the risk of inf! ection. It also has a replaceable external extension wire to t! he contr oller. This allows the external part of the wire to be replaced in case of inadvertent damage or wear from normal long term use. A new more flexible outflow cannula (the tube that directs blood from the pump to the aorta) allows greater surgical flexibility for different patient sizes and conditions. Ventracor has also updated the range of inflow cannulae sizes and surgical tools.
About Ventracor Limited
Ventracor is a global medical device company which produces an implantable blood pump, the VentrAssist left ventricular assist device (LVAD), as a therapy to improve the lives of heart failure patients. Ventracor is dedicated to building partnerships with healthcare professionals to make the VentrAssist the standard-of-care worldwide.
http://www.ventracor.com/
Visit our cardiovascular / cardiology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/92214.php>
APA
http://www.medicalnewstoday.com/releases/92214.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





